Compostable Foodservice Packaging Market
Medical Device

Gastric Cancer Diagnostic Procedure Market – Mapping the Competitive Strategy

Gastric cancer is a type of malignant cancer that forms the stomach’s inner lining. Risk factors such as age, diet, and stomach diseases can lead to the development of gastric cancer. Symptoms of gastric cancer include indigestion, heartburn, bloating, and stomach discomfort or pain. The presence of a huge patient population with gastrointestinal tumors, lymphoma, and adenocarcinoma, the increase in the geriatric population, and the rise in alcohol consumption and smoking are among the factors contributing to the growth of the gastric cancer diagnostic procedure market.

F. Hoffmann-La Roche AG. and Thermo Fisher Scientific Inc – Notable Market Players in Gastric Cancer Diagnostic Procedure Market

Key driving factors include the factors driving the gastric cancer diagnostic procedure market growth are rise in alcohol consumption and smoking. However, the shortage of medical laboratory professionals hinders the gastric cancer diagnostic procedure market growth. 

The gastric cancer diagnostic procedure market is majorly comprised of top players involving Atlas-Link Biotech Co Ltd, Bio-Rad Laboratories Inc, MiRXES Pte Ltd, Agilent Technologies Inc, F. Hoffmann-La Roche Ltd, bioMerieux SA, Thermo Fisher Scientific Inc, Illumina Inc, Vela Diagnostics Holding Pte Ltd, and Myraid Genetics Inc. among others.

The companies listed above are implementing various strategies such as product launches, acquisitions, mergers, and partnerships, which have resulted in the company’s growth and, in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.

Below is the list of the growth strategies done by the players operating in the gastric cancer diagnostic procedure market:       

Year News
Aug -2022 MiRXES launched a series of new capabilities—including an Industry 4.0
manufacturing facility, two new laboratories, and a collaborative multi-cancer
screening research project. The new developments are aligned with MiRXES’
goal of advancing its research and production capabilities to develop miRNA-based
disease detection tests.
Aug -2021 GASTROClear is the world’s first RNA-powered blood test for the
early detection of gastric cancer. The kit assesses the quantities of
12 microRNA biomarkers, allowing the company to detect as much as
87 percent of all gastric cancers. These include those at stage 0 of gastric
cancer, also known as high-grade dysplasia
Aug-2022 Roche announced the launch of the Digital LightCycler System,
Roche’s first digital polymerase chain reaction ( PCR) system.
This next-generation system detects disease and is designed to
accurately quantify trace amounts of specific DNA and RNA targets
not typically detectable by conventional PCR methods.
June-2022 Roche announced the launch of the BenchMark ULTRA PLUS system,
its newest advanced tissue staining platform. The system enables quick
and accurate test results so clinicians can make timely decisions regarding
a patient’s care journey.
Aug-2021 Myriad Genetics launched a new version of its MyRisk Hereditary Cancer Test.
The test uses advanced technologies and proprietary algorithms to evaluate 35
clinically significant genes associated with eight hereditary cancer sites, including
breast, colon, ovarian, endometrial, pancreatic, prostate, gastric cancers, and melanoma.
March-2022 Myriad Genetics launched Precise Oncology Solutions,
a new suite of tests combining germline testing, tumor profiling,
and companion diagnostic options, including evaluation for
Homologous Recombination Deficiency (HRD), an important cancer
repair pathway. The suite includes Myriad’s new Precise Tumor Molecular
Profile Test, developed in collaboration with Intermountain Precision Genomics,
other leading healthcare providers, and industry partners.

 

Leave a Reply

Your email address will not be published.